Takara Bio (4974.T) Stock Price
Takara Bio Price
Takara Bio (4974.T) Stock | ISIN JP3460200003 | WKN A0DNGL. The current Takara Bio stock price is 1,143 JPY (2026). Revenue is 42.29 B JPY. Net income is -2.49 B JPY. The P/E ratio is -55.33. Market capitalization is 137.63 B JPY. Takara Bio operates in the Health sector.
Takara Bio stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Takara Bio over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Takara Bio stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Takara Bio's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Takara Bio Price |
|---|
Takara Bio Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Takara Bio Income Statement, Balance Sheet, Cash Flow Statement
| REVENUE (M JPY) |
|---|
| REVENUE GROWTH (%) |
| GROSS MARGIN (%) |
| GROSS INCOME (M JPY) |
| NET INCOME (M JPY) |
| NET INCOME GROWTH (%) |
| DIVIDEND (JPY)DIV. (JPY) |
| DIVIDEND GROWTH (%)DIV. GROWTH (%) |
| SHARES (M) |
| DOCUMENTS |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Takara Bio generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Takara Bio retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Takara Bio's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Takara Bio has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Takara Bio's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Takara Bio stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Takara Bio Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Takara Bio business model & stock analysis
Takara Bio SWOT Analysis
Strengths
Takara Bio Inc possesses several key strengths that contribute to its success in the market. These strengths include:
- Strong research and development capabilities in the field of biotechnology.
- Wide range of innovative products and services offered to customers.
- Strong brand reputation and recognition in the industry.
- Robust distribution network allowing for efficient market reach.
- Skilled and knowledgeable workforce committed to excellence.
Weaknesses
Despite its strengths, Takara Bio Inc also faces certain weaknesses that can hinder its growth potential. These weaknesses include:
- Relatively high dependence on a specific market segment.
- Limited market share compared to some competitors.
- Possible vulnerability to changes in regulations and compliance requirements.
- Lack of strong presence in certain geographic regions.
Opportunities
Takara Bio Inc can capitalize on various opportunities available in the market to further expand and enhance its business. These opportunities include:
- Increasing demand for biotechnology products and services globally.
- Exploring new markets and regions with untapped potential.
- Potential collaborations and partnerships with other industry leaders.
- Advancements in technology that can drive innovation and product development.
- Growing focus on personalized medicine and genetic research.
Threats
Takara Bio Inc also faces several threats that pose challenges to its operations and growth. These threats include:
- Intense competition from established and emerging biotechnology companies.
- Rapidly changing market trends and customer preferences.
- Potential disruptions in the supply chain and distribution channels.
- Increasing regulatory scrutiny and compliance requirements.
- Economic uncertainties and market fluctuations.
Takara Bio Eulerpool Fair Value
Takara Bio historical P/E ratio, EBIT multiple, and P/S ratio
Takara Bio annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Takara Bio shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Takara Bio Dividend History
14 years of dividend payments
Takara Bio dividend history and estimates
Max
Details
Takara Bio dividend payout ratio
3 Years
5 Years
10 Years
25 Years
Max
Details
Takara Bio Earnings Estimates
Takara Bio Earnings Estimates
| Date | EPS estimate | Revenue Estimate | Quarterly report |
|---|---|---|---|
| 5/9/2024 | 15.05JPY | 14.83 BJPY | 2024 Q4 |
| 2/7/2024 | 7.17JPY | 11.94 BJPY | 2024 Q3 |
| 11/10/2022 | 50.8JPY | 17.57 BJPY | 2023 Q2 |
| 8/4/2022 | 34.34JPY | 14.41 BJPY | 2023 Q1 |
| 5/12/2022 | 49.29JPY | 20.55 BJPY | 2022 Q4 |
| 2/10/2022 | 20.5JPY | 13.61 BJPY | 2022 Q3 |
| 11/9/2021 | 33.23JPY | 15.57 BJPY | 2022 Q2 |
| 5/13/2021 | -JPY | 14.31 BJPY | 2021 Q4 |
| 2/10/2021 | 11.11JPY | 10.86 BJPY | 2021 Q3 |
| 11/10/2020 | 10.1JPY | 10.66 BJPY | 2021 Q2 |
Takara Bio shareholder structure
| % | Name |
|---|---|
60.91408% | |
1.73784% | |
1.12069% | |
0.82591% | |
0.75396% | |
0.69808% | |
0.43682% | |
0.41523% | |
0.39405% | |
0.39397% |
Takara Bio Executives and Management Board
Mr. Koichi Nakao
(62)President, Executive President, Chief Executive Officer, Representative Director · since 2007
Mr. Yoh Hamaoka
(62)Senior Managing Director, Senior Managing Executive Officer, Chief Financial Officer, Chief Director of Corporate · since 2004
Mr. Junichi Mineno
(64)Executive Vice President, Vice President, Chief Director of CDM Promotion, Director · since 2012
Mr. Katsuhiko Kusakabe
(63)Senior Managing Director, Senior Managing Executive Officer, Chief Manufacturing Control Officer, Chief Director of Administration · since 2017
Mr. Tsuyoshi Miyamura
(60)Senior Managing Director, Senior Managing Executive Officer, Chief Director of Overseas Business, Chairman & President of Subsidiaries · since 2009
Takara Bio Supply Chain
Frequently asked questions about Takara Bio
The business model of Takara Bio Inc revolves around providing innovative biotechnology solutions and products to the global life science industry. Takara Bio Inc primarily focuses on the development and commercialization of technologies related to genetic engineering, biomolecular detection, and amplification, as well as stem cell research. The company offers a wide range of products, including reagents, enzymes, gene editing tools, and other molecular biology tools, catering to the needs of researchers, healthcare professionals, and pharmaceutical companies. Takara Bio Inc aims to contribute to advancements in areas such as personalized medicine, agriculture, and environmental conservation through its cutting-edge biotechnological solutions.
Takara Bio stock
Takara Bio Peer Group
Takara Bio Ticker
Takara Bio FIGI
All fundamentals and in-depth analysis of Takara Bio
Our stock analysis for Takara Bio Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Takara Bio Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.